atorvastatin elc 20mg film-coated tablets
basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 20 mg - lipid modifying agents
atorvastatin elc 40mg film-coated tablets
basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 40 mg - lipid modifying agents
atorvastatin elc 80mg film-coated tablets
basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 80 mg - lipid modifying agents
ezetimibe/atorvastatin althera 10 mg/10 mg film-coated tablet
althera laboratories ltd 1st floor, 9 exchange place, i.f.s.c. dublin 1, ireland - ezetimibe, atorvastatin - film-coated tablet - ezetimibe 10 mg atorvastatin 10 mg - lipid modifying agents
atorvastatin momaja 10mg film-coated tablets
basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 10 mg - lipid modifying agents
atorvastatin momaja 20mg film-coated tablets
basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 20 mg - lipid modifying agents
atorvastatin momaja 40mg film-coated tablets
basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 40 mg - lipid modifying agents
atorvastatin momaja 80mg film-coated tablets
basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 80 mg - lipid modifying agents
ezetimibe tablet
amneal pharmaceuticals ny llc - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24) - ezetimibe 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. monotherapy ezetimibe tablets, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. combination therapy with hmg-coa reductase inhibitors (statins) ezetimibe tablets, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elev
ezetimibe tablet
major pharmaceuticals - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24) - ezetimibe 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. monotherapy ezetimibe, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), and non- high-density lipoprotein cholesterol (non-hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. combination therapy with hmg-coa reductase inhibitors (statins) ezetimibe, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated to